Eiger BioPharmaceuticals Status
The company (NASDAQ:EIGR) recieved $3 million of development capital from HBM Healthcare Investments on May 2, 2016. Previously, the company acquired Celladon through a reverse merger, resulting in the combined entity trading on the NASDAQ Stock Exchange under the ticker symbol EIGR on March 22, 2016.
Leave a Reply ·
You must be logged in to post a comment.